-
公开(公告)号：US20090175881A1
公开(公告)日：2009-07-09
申请号：US11836318
申请日：2007-08-09
IPC分类号： A61K39/395 , C07K16/24 , C07H21/00 , C12N15/63 , C12N5/00 , C12P21/00 , A61P29/00 , A61P37/06
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Engineered antibodies to human IL-17A are provided, as well as uses thereof.
摘要翻译： 提供了人IL-17A的工程抗体及其用途。
-
公开(公告)号：US20090081707A1
公开(公告)日：2009-03-26
申请号：US12157753
申请日：2008-06-13
申请人： Leonard G. Presta , David L. Shelton , Roman Urfer
发明人： Leonard G. Presta , David L. Shelton , Roman Urfer
IPC分类号： G01N33/53
CPC分类号： C07K14/71 , A61K38/00 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
-
公开(公告)号：US07351816B2
公开(公告)日：2008-04-01
申请号：US10968237
申请日：2004-10-19
IPC分类号： C07H21/04
CPC分类号： C07K16/00 , A61K38/00 , C07K16/18 , C07K16/32 , C07K16/4291 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/565 , C07K2319/00
摘要： The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.
摘要翻译： 本发明描述了IgE拮抗剂（包括变体抗IgE抗体）及其在诊断，治疗或预防过敏性和其它IgE介导的障碍（包括哮喘，食物过敏，超敏反应和过敏反应）中的用途。
-
公开(公告)号：US06800738B1
公开(公告)日：2004-10-05
申请号：US09705398
申请日：2000-11-02
申请人： Paul J. Carter , Leonard G. Presta
发明人： Paul J. Carter , Leonard G. Presta
IPC分类号： C12P2108
CPC分类号： C07K16/2845 , A61K38/00 , C07K16/00 , C07K16/28 , C07K16/2809 , C07K16/32 , C07K16/465 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2319/00 , G06F15/00
摘要： Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
摘要翻译： 提供了变体免疫球蛋白，特别是人源化抗体多肽，以及其制备和使用方法。 还提供了共同的免疫球蛋白序列和结构模型。
-
公开(公告)号：US06685939B2
公开(公告)日：2004-02-03
申请号：US09802096
申请日：2001-03-08
IPC分类号： A61K39395
CPC分类号： C07K16/00 , A61K38/00 , C07K16/18 , C07K16/32 , C07K16/4291 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/565 , C07K2319/00
摘要： The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.
摘要翻译： 本发明描述了IgE拮抗剂（包括变体抗IgE抗体）及其在诊断，治疗或预防过敏性和其它IgE介导的障碍（包括哮喘，食物过敏，超敏反应和过敏反应）中的用途。
-
公开(公告)号：US06528624B1
公开(公告)日：2003-03-04
申请号：US09282846
申请日：1999-03-31
IPC分类号： C12P2108
CPC分类号： C07K16/4291 , A61K38/00 , A61K47/6849 , A61K47/6873 , C07K16/00 , C07K16/22 , C07K16/2896 , C07K2317/21 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
-
公开(公告)号：US6121022A
公开(公告)日：2000-09-19
申请号：US422112
申请日：1995-04-14
CPC分类号： C07K16/2845 , C07K2317/52 , C07K2317/54 , C07K2317/55
摘要： Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
摘要翻译： 从肾脏中清除并且不以其原始形式含有IgG的Fc区的多肽被改变，以便包含IgG的Fc区的补救受体结合表位，从而具有增加的循环半衰期。
-
公开(公告)号：US6037454A
公开(公告)日：2000-03-14
申请号：US974899
申请日：1997-11-20
IPC分类号： A61K39/395 , C07K16/28 , C12P21/08 , C07H21/04 , C12N15/13
CPC分类号： C07K16/2845 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2319/00
摘要： Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.
摘要翻译： 公开了人源化抗CD11a抗体及其各种用途。 和/或表达ICA-1的人类抗CD11a抗体可以特异性结合人CD11a I-结构域，具有不大于约1nM的IC 50（nM）值以防止Jurkat细胞粘附到正常的人表皮角化细胞上，和/或 在混合淋巴细胞反应测定中IC50（nM）值不超过约1nM。
-
公开(公告)号：US6025166A
公开(公告)日：2000-02-15
申请号：US444622
申请日：1995-05-19
申请人： Leonard G. Presta , David L. Shelton , Roman Urfer
发明人： Leonard G. Presta , David L. Shelton , Roman Urfer
IPC分类号： G01N33/53 , A61K38/00 , A61K38/55 , A61K39/395 , A61P1/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P25/18 , A61P25/28 , A61P29/00 , A61P35/00 , C07H21/04 , C07K14/705 , C07K14/71 , C07K16/28 , C07K19/00 , C12N15/02 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68 , C12P21/04 , C07H21/02
CPC分类号： C07K14/71 , C07K19/00 , A61K38/00 , C07K2319/00 , C07K2319/30
摘要： The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns imnunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
摘要翻译： 本发明涉及人trkB和trkC受体及其功能衍生物。 本发明还涉及包含与免疫球蛋白序列融合的trk受体序列的抑制素。
-
40.发明授权Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment 失效具有纤维蛋白特异性的组织纤溶酶原激活剂和氨基酸466-970的缺失，组合物和治疗方法
公开(公告)号：US5258180A
公开(公告)日：1993-11-02
申请号：US744614
申请日：1991-08-13
申请人： John F. Gill , Leonard G. Presta , Mark J. Zoller
发明人： John F. Gill , Leonard G. Presta , Mark J. Zoller
CPC分类号： C12N9/6459 , C12Y304/21069 , A61K38/00
摘要： A tissue plasminogen activator (t-PA) variant is prepared that has an amino acid deletion at positions 466 to 470 of the corresponding wild-type t-PA. This alteration renders the variant fibrin (and plasma clot) specific as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the variant, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The variant may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
摘要翻译： 制备组织纤溶酶原激活物（t-PA）变体，其在相应野生型t-PA的466至470位具有氨基酸缺失。 与相应的野生型t-PA相比，这种改变使得变体纤维蛋白（和血浆凝块）特异性。 可以制备编码变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 该变体可用于药物制剂中以治疗血管疾病或病症或预防哺乳动物中的纤维蛋白沉积或粘附形成或重组。
-
-
-
-
-
-
-
-
-
搜索结果
167 条记录 (耗时 0.091 秒)
